CpG Island Methylation in Sessile Serrated Adenoma/Polyp of the Colorectum: Implications for Differential Diagnosis of Molecularly High-Risk Lesions among Non-dysplastic Sessile Serrated Adenomas/Polyps
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Although colorectal sessile serrated adenomas/polyps (SSA/Ps) with morphologic dysplasia are regarded as definite high-risk premalignant lesions, no reliable grading or risk-stratifying system exists for non-dysplastic SSA/Ps. The accumulation of CpG island methylation is a molecular hallmark of progression of SSA/Ps. Thus, we decided to classify non-dysplastic SSA/Ps into risk subgroups based on the extent of CpG island methylation. Methods: The CpG island methylator phenotype (CIMP) status of 132 non-dysplastic SSA/Ps was determined using eight CIMP-specific promoter markers. SSA/Ps with CIMP-high and/or MLH1 promoter methylation were regarded as a high-risk subgroup. Results: Based on the CIMP analysis results, methylation frequency of each CIMP marker suggested a sequential pattern of CpG island methylation during progression of SSA/P, indicating MLH1 as a late-methylated marker. Among the 132 non-dysplastic SSA/Ps, 34 (26%) were determined to be high-risk lesions (33 CIMP-high and 8 MLH1-methylated cases; seven cases overlapped). All 34 high-risk SSA/Ps were located exclusively in the proximal colon (100%, p = .001) and were significantly associated with older age (≥ 50 years, 100%; p = .003) and a larger histologically measured lesion size (> 5 mm, 100%; p = .004). In addition, the high-risk SSA/Ps were characterized by a relatively higher number of typical base-dilated serrated crypts. Conclusions: Both CIMP-high and MLH1 methylation are late-step molecular events during progression of SSA/Ps and rarely occur in SSA/Ps of young patients. Comprehensive consideration of age (≥ 50), location (proximal colon), and histologic size (> 5 mm) may be important for the prediction of high-risk lesions among non-dysplastic SSA/Ps.
Abstract
Background: Although colorectal sessile serrated adenomas/polyps (SSA/Ps) with morphologic dysplasia are regarded as definite high-risk premalignant lesions, no reliable grading or risk-stratifying system exists for non-dysplastic SSA/Ps. The accumulation of CpG island methylation is a molecular hallmark of progression of SSA/Ps. Thus, we decided to classify non-dysplastic SSA/Ps into risk subgroups based on the extent of CpG island methylation. Methods: The CpG island methylator phenotype (CIMP) status of 132 non-dysplastic SSA/Ps was determined using eight CIMP-specific promoter markers. SSA/Ps with CIMP-high and/or MLH1 promoter methylation were regarded as a high-risk subgroup. Results: Based on the CIMP analysis results, methylation frequency of each CIMP marker suggested a sequential pattern of CpG island methylation during progression of SSA/P, indicating MLH1 as a late-methylated marker. Among the 132 non-dysplastic SSA/Ps, 34 (26%) were determined to be high-risk lesions (33 CIMP-high and 8 MLH1-methylated cases; seven cases overlapped). All 34 high-risk SSA/Ps were located exclusively in the proximal colon (100%, p = .001) and were significantly associated with older age (≥ 50 years, 100%; p = .003) and a larger histologically measured lesion size (> 5 mm, 100%; p = .004). In addition, the high-risk SSA/Ps were characterized by a relatively higher number of typical base-dilated serrated crypts. Conclusions: Both CIMP-high and MLH1 methylation are late-step molecular events during progression of SSA/Ps and rarely occur in SSA/Ps of young patients. Comprehensive consideration of age (≥ 50), location (proximal colon), and histologic size (> 5 mm) may be important for the prediction of high-risk lesions among non-dysplastic SSA/Ps.
참고문헌 (26)
- Bae JM, "Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway", Arch Pathol Lab Med, 140, pp.406~412 (2016)
- Lochhead P, "Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions", Am J Gastroenterol, 109, pp.1205~1214 (2014)
- Snover DC, "Update on the serrated pathway to colorectal carcinoma", Hum Pathol, 42, pp.1~10 (2011)
- Batts KP, "The pathology of serrated colorectal neoplasia: practical answers for common questions", Mod Pathol, 28(Suppl 1), pp.S80~S87 (2015)
- Bosman FT, "WHO classification of tumours of the digestive system" (2010), International Agency for Research on Cancer
- Rex DK, "Serrated lesions of the colorectum : review and recommendations from an expert panel", Am J Gastroenterol, 107, pp.1315~1329 (2012)
- IJspeert JE, "Serrated neoplasiarole in colorectal carcinogenesis and clinical implications", Nat Rev Gastroenterol Hepatol, 12, pp.401~409 (2015)
- Kim JH, "Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype : implications in the serrated neoplasia pathway", Oncotarget, 7, pp.14095~14111 (2016)
- Bateman AC, "UK guidance for the pathological reporting of serrated lesions of the colorectum", J Clin Pathol, 68, pp.585~591 (2015)
- Crockett SD, "Sessile serrated adenomas : an evidence-based guide to management", Clin Gastroenterol Hepatol, 13, pp.11~26 (2015)[DOI]
- Parker HR, "The proto CpG island methylator phenotype of sessile serrated adenomas", polyps, 2018, pp.13, 1088~1105
- Sakai E, "Accumulation of aberrant DNA methylation during colorectal cancer development", World J Gastroenterol, 20, pp.978~987 (2014)
- Bae JM, "Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma", Mod Pathol, 30, pp.267~277 (2017)
- 오현정, "Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II", III Colorectal Cancers Treated with Adjuvant Chemotherapy, 2019, pp.53(1), 40~49[DOI]
- Ogino S, "CpG island methylator phenotype(CIMP)of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies", Gut, 55, pp.1000~1006 (2006)
- Ogino S, "Evaluation of markers for CpG island methylator phenotype(CIMP)in colorectal cancer by a large population-based sample", J Mol Diagn, 9, pp.305~314 (2007)
- Nosho K, "Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample", PLoS One, 3, pp.e3698~ (2008)
- Kim JH, "Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers", Virchows Arch, 455, pp.485~494 (2009)
- Wen X, "Improved results of LINE-1 methylation analysis in formalin-fixed, paraffin-embedded tissues with the application of a heating step during the DNA extraction process", Clin Epigenetics, 9, pp.1~ (2017)
- Bettington M, "Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma", Gut, 66, pp.97~106 (2017)
- Burgess NG, "Sessile serrated adenomas", polyps with cytologic dysplasia : a triple threat for interval cancer, 2014, pp.80, 307~310
- Weisenberger DJ, "CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer", Nat Genet, 38, pp.787~793 (2006)
- Liu C, "CpG island methylation in sessile serrated adenomas increases with age, indicating lower risk of malignancy in young patients", Gastroenterology, 155, pp.1362.e2~1365.e2 (2018)
- Bettington M, "Sessile serrated adenomas in young patients may have limited risk of malignant progression", J Clin Gastroenterol, 53, pp.e113~e116 (2019)
- He EY, "The molecular characteristics of colonic neoplasms in serrated polyposis : a systematic review and meta-analysis", J Pathol Clin Res, 2, pp.127~137 (2016)
- Edelstein DL, "Serrated polyposis : rapid and relentless development of colorectal neoplasia", Gut, 62, pp.404~408 (2013)